The Journal of Practical Medicine >
Research advances in allergen-specific immunotherapy
Received date: 2025-01-05
Online published: 2025-06-19
Allergic diseases represent a significant global health challenge， and allergen-specific immunotherapy （AIT）， as a first-line treatment， is the only therapeutic approach capable of altering the natural course of these diseases. This article provides a systematic review of the major advancements in AIT over recent years， encompassing novel routes of administration， the integration of biologics and adjuvants， advancements in allergen preparation， strategies for adverse reaction prevention and management， and efficacy evaluation methods. Among the new routes of administration， intratympanic， intratonsillar， epicutaneous， and intranasal immunotherapies have demonstrated safety， efficacy， and enhanced patient adherence. Biologics such as omalizumab， dupilumab， and Tezepelumab， each with distinct anti-allergic mechanisms， reduce adverse reactions and optimize outcomes when combined with AIT. The use of adjuvants represents another strategy to enhance AIT efficacy； agents like β-glucans， mannan， CpG oligodeoxynucleotides （CpG-ODN）， liposomes， and nanoparticles stimulate immune responses， promote immune tolerance， and improve the therapeutic effects of AIT. Recombinant allergens， produced through genetic engineering， offer high purity and consistency， providing more reliable and reproducible therapeutic results for AIT. In summary， this review highlights the latest developments in various approaches aimed at enhancing AIT efficacy， offering new insights into the treatment of allergic diseases.
Zegong HU , Yan BAI . Research advances in allergen-specific immunotherapy[J]. The Journal of Practical Medicine, 2025 , 41(11) : 1760 -1766 . DOI: 10.3969/j.issn.1006-5725.2025.11.022
| 1 | BERREIROS-HORTALA H， VILCHEZ-PINTO G， DIAZ-PERALES A， et al. Virus-like Particles as Vaccines for Allergen-Specific Therapy： An Overview of Current Developments［J］. Int J Mol Sci， 2024， 25（13）： 7429. doi:10.3390/ijms25137429 |
| 2 | 过敏性鼻炎皮下免疫治疗专家共识2015［J］. 中国耳鼻咽喉头颈外科， 2015， 22（8）： 379-404. |
| 3 | 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组中. 中国变应性鼻炎诊断和治疗指南（2022年，修订版）［J］. 中华耳鼻咽喉头颈外科杂志， 2022， 57（2）： 106-129. |
| 4 | LIU J， YIN J. A retrospective analysis of the clinical efficacy in patients treated with Alternaria alternata and Dermatophagoides farinae immunotherapy［J］. Front Allergy， 2024， 5： 1453446. doi:10.3389/falgy.2024.1453446 |
| 5 | HOFFMANN H J， HVIID-VYFF B. Strengthening the case for intralymphatic immunotherapy［J］. Curr Opin Allergy Clin Immunol， 2022， 22（6）： 387-395. doi:10.1097/aci.0000000000000857 |
| 6 | LIN Y J， ZIMMERMANN J， SCHüLKE S. Novel adjuvants in allergen-specific immunotherapy： Where do we stand？［J］. Front Immunol， 2024， 15： 1348305. doi:10.3389/fimmu.2024.1348305 |
| 7 | DANTZER J A， WOOD R A. Update on omalizumab in allergen immunotherapy［J］. Curr Opin Allergy Clin Immunol， 2021， 21（6）： 559-568. doi:10.1097/aci.0000000000000781 |
| 8 | TIE K， MILLER C， ZANATION A M， et al. Subcutaneous Versus Sublingual Immunotherapy for Adults with Allergic Rhinitis： A Systematic Review with Meta-Analyses［J］. Laryngoscope， 2022， 132（3）： 499-508. doi:10.1002/lary.29586 |
| 9 | JUNG J H， KIM K A， CHOI Y S， et al. Effect of intralymphatic allergen-specific immunotherapy on house dust mite in a murine model of allergic rhinitis［J］. Acta Otolaryngol， 2023， 143（10）： 867-875. doi:10.1080/00016489.2023.2273405 |
| 10 | HJALMARSSON E， HELLKVIST L， KARLSSON A， et al. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects［J］. J Investig Allergol Clin Immunol， 2023， 33（5）： 362-372. doi:10.18176/jiaci.0832 |
| 11 | KHOSHKHUI M， JABBARI F， SHAFIEE ZARGAR F， et al. Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis［J］. Iran J Allergy Asthma Immunol， 2024， 23（2）： 149-157. |
| 12 | ZHANG J， YANG X， CHEN G， et al. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis： A randomized， double-blind， placebo-controlled clinical trial［J］. Ann Allergy Asthma Immunol， 2024， 132（3）： 346-354.e1. doi:10.1016/j.anai.2023.10.029 |
| 13 | GU T， ZHANG W， TAN L， et al. Intratonsillar Immunotherapy： A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis［J］. Research （Wash D C）， 2025， 8： 0573. doi:10.34133/research.0573 |
| 14 | GREENHAWT M， SINDHER S B， WANG J， et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy［J］. N Engl J Med， 2023， 388（19）： 1755-1766. |
| 15 | PARIS J L， VORA L K， TORRES M J， et al. Microneedle array patches for allergen-specific immunotherapy［J］. Drug Discov Today， 2023， 28（5）： 103556. doi:10.1016/j.drudis.2023.103556 |
| 16 | LIU J， XIAO X， LIAO Y， et al. Allergen specific immunotherapy regulates macrophage property in the airways［J］. Arch Biochem Biophys， 2024， 755： 109984. doi:10.1016/j.abb.2024.109984 |
| 17 | ASHLEY S E， BOSCO A， TANG M L K. Transcriptomic changes associated with oral immunotherapy for food allergy［J］. Pediatr Allergy Immunol， 2024， 35（3）： e14106. doi:10.1111/pai.14106 |
| 18 | ZHANG H Z， XIE W， ZHOU W C， et al. Oral immunotherapy with enteric-coated capsules for allergic rhinitis caused by house dust mites［J］. Front Allergy， 2024， 5： 1345929. doi:10.3389/falgy.2024.1345929 |
| 19 | CANONICA G W， VARRICCHI G， PAOLETTI G， et al. Advancing precision medicine in asthma： Evolution of treatment outcomes［J］. J Allergy Clin Immunol， 2023， 152（4）： 835-840. doi:10.1016/j.jaci.2023.07.009 |
| 20 | ZHANG Y Y， ZHANG M， ZHANG J Q， et al. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases： A meta-analysis of randomized controlled trials［J］. Int Forum Allergy Rhinol， 2024， 14（4）： 794-806. doi:10.1002/alr.23268 |
| 21 | BO?EK A， FISCHER A， BOGACZ-PIASECZYNSKA A， et al. Adding a biologic to allergen immunotherapy increases treatment efficacy［J］. ERJ Open Res， 2023， 9（2）： 00639-2022. doi:10.1183/23120541.00639-2022 |
| 22 | HARB H， CHATILA T A. Mechanisms of Dupilumab［J］. Clin Exp Allergy， 2020， 50（1）： 5-14. doi:10.1111/cea.13491 |
| 23 | DENG S， WANG H， CHEN S， et al. Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis： A preliminary report［J］. Int Immunopharmacol， 2023， 125（Pt A）： 111137. doi:10.1016/j.intimp.2023.111137 |
| 24 | KIM J， BOO J， JANG H， et al. Combined Dupilumab and Allergen-Specific Immunotherapy in Severe Refractory Atopic Dermatitis［J］. Allergy Asthma Immunol Res， 2024， 16（6）： 682-689. doi:10.4168/aair.2024.16.6.682 |
| 25 | CORREN J， LARSON D， ALTMAN M C， et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen： A randomized controlled trial［J］. J Allergy Clin Immunol， 2023， 151（1）： 192-201. doi:10.1016/j.jaci.2022.08.029 |
| 26 | RAINER H， GORETZKI A， LIN Y J， et al. Characterization of the Immune-Modulating Properties of Different β-Glucans on Myeloid Dendritic Cells［J］. Int J Mol Sci， 2024， 25（18）： 9914. doi:10.3390/ijms25189914 |
| 27 | BENITO-VILLALVILLA C， PéREZ-DIEGO M， ANGELINA A， et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring［J］. J Allergy Clin Immunol， 2022， 149（1）： 212-222.e9. doi:10.1016/j.jaci.2021.06.012 |
| 28 | SORIA I， LóPEZ-RELA?O J， VI?UELA M， et al. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice［J］. Allergy， 2018， 73（4）： 875-884. doi:10.1111/all.13396 |
| 29 | OJEDA P， BARJAU M C， SUBIZA J， et al. Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy： A dose-finding study［J］. Front Immunol， 2024， 15： 1431351. doi:10.3389/fimmu.2024.1431351 |
| 30 | CANNON A S， NAGARKATTI P S， NAGARKATTI M. Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases［J］. Int J Mol Sci， 2021， 23（1）： 288. doi:10.3390/ijms23010288 |
| 31 | HEINE S， ALESSANDRINI F， GROSCH J， et al. Activation of the aryl hydrocarbon receptor improves allergen-specific immunotherapy of murine allergic airway inflammation： A novel adjuvant option？［J］. Front Immunol， 2024， 15：1397072. doi:10.3389/fimmu.2024.1397072 |
| 32 | LEONARD C， MONTAMAT G， DAVRIL C， et al. Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant［J］. Allergy， 2021， 76（7）： 2153-2165. doi:10.1111/all.14716 |
| 33 | KIRTLAND M E， TSITOURA D C， DURHAM S R， et al. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy［J］. Front Immunol， 2020， 11： 599083. doi:10.3389/fimmu.2020.599083 |
| 34 | ZENG H， XU L， LIU J， et al. Regulation of Tert methylation alleviates food allergy via regulating the Tert-IL10 signal pathway［J］. Immunol Res， 2024， 72（5）： 1018-1029. doi:10.1007/s12026-024-09504-6 |
| 35 | ZHANG A， MO L， CHEN X， et al. Direct exposure to CpG and specific antigens mitigate airway allergy through modulating dendritic cell properties［J］. Biomed Pharmacother， 2024， 174： 116510. doi:10.1016/j.biopha.2024.116510 |
| 36 | FENG Z， YI X， HAJAVI J. New and old adjuvants in allergen-specific immunotherapy： With a focus on nanoparticles［J］. J Cell Physiol， 2021， 236（2）： 863-876. doi:10.1002/jcp.29941 |
| 37 | PENG X， GE Y， LI W， et al. Targeting Lewis X oligosaccharide-modified liposomes encapsulated with house dust mite allergen Der f 2 to dendritic cells inhibits Th2 immune response［J］. Eur J Pharm Sci， 2023， 190： 106570. doi:10.1016/j.ejps.2023.106570 |
| 38 | 许姣，张旻，谢国钢. 肥大细胞来源的外泌体在支气管哮喘中的研究进展［J］. 实用医学杂志， 2024， 40（15）： 2194-2198. |
| 39 | MIRON R J， ESTRIN N E， SCULEAN A， et al. Understanding exosomes： Part 2—Emerging leaders in regenerative medicine［J］. Periodontol，2000， 2024， 94（1）： 257-414. |
| 40 | FANG S B， ZHANG H Y， WANG C， et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p［J］. J Extracell Vesicles， 2020， 9（1）： 1723260. doi:10.1080/20013078.2020.1723260 |
| 41 | DEHNAVI S， DADMANESH M， HOSSEINI ROUZBAHANI N， et al. Mesenchymal Stem Cell-derived Exosome； An Interesting Nanocarrier to Improve Allergen-specific Intranasal Immunotherapy［J］. Iran J Allergy Asthma Immunol， 2023， 22（6）： 561-574. |
| 42 | BAKER J R JR， RASKY A J， LANDERS J J， et al. Intranasal delivery of allergen in a nanoemulsion adjuvant inhibits allergen-specific reactions in mouse models of allergic airway disease［J］. Clin Exp Allergy， 2021， 51（10）： 1361-1373. doi:10.1111/cea.13903 |
| 43 | ZENG Y， ZHOU W K. Aluminum hydroxide nanoparticle adjuvants can reduce the inflammatory response more efficiently in a mouse model of allergic asthma than traditional aluminum hydroxide adjuvants［J］. Exp Ther Med， 2024， 27（1）： 39. doi:10.3892/etm.2023.12327 |
| 44 | LIU J， YIN J. Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice［J］. Front Immunol， 2021， 12： 747730. doi:10.3389/fimmu.2021.747730 |
| 45 | WANG T， CHI J， LI Z， et al. Recombinant Art v4.01 protein produces immunological tolerance by subcutaneous immunotherapy in a wormwood pollen-driven allergic asthma female mouse model［J］. PLoS One， 2024， 19（6）： e0280418. doi:10.1371/journal.pone.0280418 |
| 46 | ASOUDEH MOGHANLOO S， FOROUZANFAR M， JAFARINIA M， et al. Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model［J］. Immun Inflamm Dis， 2023， 11（6）： e878. doi:10.1002/iid3.878 |
| 47 | ZHOU D， REN Y， ZHOU Y， et al. Expression， purification， and activity of novel allergen Tyr p 31 from Tyrophagus putrescentiae［J］. Int J Biol Macromol， 2024， 258： 128856. doi:10.1016/j.ijbiomac.2023.128856 |
| 48 | PROTI?-ROSI? I， NE?I? A， LUKI? I， et al. Recombinant Bet v 1-BanLec chimera modulates functional characteristics of peritoneal murine macrophages by promoting IL-10 secretion［J］. Mol Immunol， 2021， 138： 58-67. doi:10.1016/j.molimm.2021.06.015 |
| 49 | KHAITOV M， SHILOVSKIY I， VALENTA R， et al. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy［J］. Allergy， 2024， 79（4）： 1001-1017. doi:10.1111/all.15919 |
| 50 | RAUBER M M， M?BS C， CAMPANA R， et al. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells［J］. Allergy， 2020， 75（2）： 450-453. doi:10.1111/all.13996 |
| 51 | YANG L， ZHU R. Allergen Preparation in AIT， Now and in the Future［J］. Curr Treat Options Allergy， 2021， 8（2）： 120-132. doi:10.1007/s40521-021-00281-3 |
| 52 | SPIRIC J， SCHULENBORG T， HOLZHAUSER T， et al. Quality control of allergen products with mass spectrometry part I： Positioning within the EU regulatory framework［J］. Allergy， 2024， 79（8）： 2088-2096. doi:10.1111/all.16080 |
| 53 | LI Y， XIAO H， ZENG Y， et al. Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis［J］. Iran J Allergy Asthma Immunol， 2024， 23（1）： 52-58. |
| 54 | WU J， WANG D， HE W J， et al. Allergen-specific sublingual immunotherapy altered gut microbiota in patients with allergic rhinitis［J］. Front Cell Infect Microbiol， 2024， 14： 1454333. doi:10.3389/fcimb.2024.1454333 |
| 55 | MCKENZIE C I， VARESE N， AUI P M， et al. RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy： Two unique cell fates and CD29 as a biomarker for treatment effect［J］. Allergy， 2023， 78（3）： 822-835. doi:10.1111/all.15529 |
| 56 | KARALI Z， ?EKI? ?， ?ADIRVAN Y H， et al. The Evaluation of Local and Systemic Reactions to Subcutaneous House Dust Mite Allergen Immunotherapy［J］. Trends Pediatrics， 2022， 3（2）： 43-46. doi:10.4274/tp.galenos.2022.46320 |
| 57 | ALTAS U， CETEMEN A， ALTAS Z M， et al. Retrospective evaluation of adverse reactions after subcutaneous allergen-specific immunotherapy in children with house dust mite allergy［J］. North Clin Istanb， 2023， 10（5）： 675-680. |
| 58 | 唐隽， 王向东， 王洪田， 等. 变应原淋巴结内注射免疫治疗变应性鼻炎临床指引［J］. 中国眼耳鼻喉科杂志， 2025， 25（1）： 36-42. |
| 59 | 刘晓， 李佳钰， 陈壮桂，等. 儿童尘螨变应原皮下特异性免疫治疗的研究进展［J］. 新医学， 2024， 55（11）： 936-943. |
| 60 | KATHURIA P C， RAI M. Omalizumab with allergen immunotherapy in respiratory & food allergy［J］. Indian J Tuberc， 2025， 72（1）： 98-102. doi:10.1016/j.ijtb.2024.06.011 |
| 61 | 中国医药教育协会儿科专业委员会， 中华医学会儿科学分会呼吸学组哮喘协作组， 福棠儿童医学发展研究中心过敏（变态）反应学科规范化建设研究组. 儿童过敏性哮喘尘螨过敏原特异性免疫治疗循证指南（医生版）［J］. 中华实用儿科临床杂志， 2024， 39（6）： 401-417. |
| 62 | FRITZSCHING B， CONTOLI M， PORSBJERG C， et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma： Results from the REACT study， a retrospective cohort study［J］. Lancet Reg Health Eur， 2022， 13： 100275. doi:10.1016/j.lanepe.2021.100275 |
/
| 〈 |
|
〉 |